Michael Barbella, Managing Editor06.24.24
Allez Health Inc. formerly known as Zense-Life Inc., is $60 million richer these days, having conducted a Series A+ financing round led by Korean in-vitro diagnostics company Osang Healthcare Co. Ltd. as a strategic investor, and participation from existing investors. The new capital will be used to help fund pivotal clinical trials, support regulatory approval filings, and scale manufacturing operations.
“Since the founding of Allez Health, we have been impressed by their progress and are excited to officially forge a strong collaboration with them,” Osang Healthcare CEO Dr. Chulhun Kang said. “Their design and technical advances, coupled with Osang’s manufacturing capability and global reach, will bring meaningful access to CGM technology for millions of people with diabetes as well as the broader wellness market.”
Allez Health is a pioneering CGM biosensor platform with novel sensor technology that aims to disrupt the current cost barrier while enhancing performance and user experience. Since its inception, Allez Health has accomplished several milestones including seven issued patents and more than 40 pending patent applications, over 80 clinical studies aggregating more than 1,500 users, and a pivotal study in 120 insulin users. Having completed the pivotal study and having secured key strategic investment as well as select distribution and manufacturing arrangements, Allez Health expects to accelerate its progress toward commercialization in multiple global markets, assuming the timely receipt of the necessary regulatory approvals and the continued availability of capital.
“We believe that person-centric health is critical for optimal health solutions,” Allez Health Co-Founder/CEO Leif Bowman stated. “We aim to bring to market a sensor that combines access, affordability, and reliable performance, because when it comes to an individual’s health, no one should have to choose between price and performance.”
Allez Health Inc. is a an emerging biosensor company focused on connected digital health platforms. The Allez Health sensor is an investigational device that is not yet cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority. The company was founded by proven experts in the continuous glucose monitoring space.
“Since the founding of Allez Health, we have been impressed by their progress and are excited to officially forge a strong collaboration with them,” Osang Healthcare CEO Dr. Chulhun Kang said. “Their design and technical advances, coupled with Osang’s manufacturing capability and global reach, will bring meaningful access to CGM technology for millions of people with diabetes as well as the broader wellness market.”
Allez Health is a pioneering CGM biosensor platform with novel sensor technology that aims to disrupt the current cost barrier while enhancing performance and user experience. Since its inception, Allez Health has accomplished several milestones including seven issued patents and more than 40 pending patent applications, over 80 clinical studies aggregating more than 1,500 users, and a pivotal study in 120 insulin users. Having completed the pivotal study and having secured key strategic investment as well as select distribution and manufacturing arrangements, Allez Health expects to accelerate its progress toward commercialization in multiple global markets, assuming the timely receipt of the necessary regulatory approvals and the continued availability of capital.
“We believe that person-centric health is critical for optimal health solutions,” Allez Health Co-Founder/CEO Leif Bowman stated. “We aim to bring to market a sensor that combines access, affordability, and reliable performance, because when it comes to an individual’s health, no one should have to choose between price and performance.”
Allez Health Inc. is a an emerging biosensor company focused on connected digital health platforms. The Allez Health sensor is an investigational device that is not yet cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority. The company was founded by proven experts in the continuous glucose monitoring space.